| Fiscal Period | 2024 | 2023 | 2022 |
|---|---|---|---|
| Period End Date | Mar 24 | Mar 23 | Mar 22 |
| Revenue | 1,016.94 | 1,361.79 | 1,132.32 |
| Total Revenue | 1,016.94 | 1,361.79 | 1,132.32 |
| Costof Revenue Total | 229.20 | 2.52 | 6.70 |
| Gross Profit | 787.74 | 1,359.27 | 1,125.63 |
| Selling/ General/ Admin Expenses Total | 123.05 | 1,034.30 | 802.62 |
| Depreciation/ Amortization | 53.59 | 47.13 | 42.28 |
| Other Operating Expenses Total | 233.14 | 1.79 | 1.44 |
| Total Operating Expense | 638.97 | 1,131.23 | 879.44 |
| Operating Income | 377.97 | 230.55 | 252.89 |
| Interest Inc( Exp) Net- Non- Op Total | 8.19 | 8.88 | 102.89 |
| Other Net | 33.78 | -3.24 | -2.08 |
| Net Income Before Taxes | 412.57 | 228.49 | 262.20 |
| Provisionfor Income Taxes | 104.46 | 36.27 | 60.15 |
| Net Income After Taxes | 308.10 | 192.22 | 202.06 |
| Net Income Before Extra Items | 308.10 | 192.22 | 202.06 |
| Net Income | 308.10 | 192.22 | 202.06 |
| Income Availableto Com Excl Extra Ord | 308.10 | 192.22 | 202.06 |
| Income Availableto Com Incl Extra Ord | 308.10 | 192.22 | 202.06 |
| Diluted Net Income | 308.10 | 192.22 | 202.06 |
| Diluted Weighted Average Shares | 10.46 | 13.46 | 13.46 |
| Diluted EPS Excluding Extra Ord Items | 29.45 | 14.28 | 15.01 |
| DPS- Common Stock Primary Issue | 8.75 | - | - |
| Diluted Normalized EPS | 29.45 | 17.10 | 16.46 |
| Unusual Expense( Income) | - | 45.50 | 26.39 |
| Gain( Loss)on Saleof Assets | - | 2.88 | 11.10 |
Concord Biotech Dividend Concord Biotech Bonus Concord Biotech News Concord Biotech AGM Concord Biotech Rights Concord Biotech Splits Concord Biotech Board Meetings Concord Biotech Key Metrics Concord Biotech Shareholdings Concord Biotech Balance Sheet Concord Biotech Cashflow Concord Biotech Q1 Results Concord Biotech Q2 Results Concord Biotech Q3 Results Concord Biotech Q4 Results
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks